A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...

The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years. More than half of all women ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Gepotidacin is an oral ... and vulvovaginal candidiasis. “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific ...

The FDA has approved GSK’s gepotidacin (Blujepa) for treating uncomplicated urinary tract infections (uUTIs) in females aged 12 and older. The approval is based on successful phase 3 EAGLE-2 ...

Blujepa, the first new oral antibiotic for UTIs in 30 years, works by targeting bacterial DNA replication through dual ...